17-63947082-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000334.4(SCN4A):c.3404G>A(p.Arg1135His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000274 in 1,461,126 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1135C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000334.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SCN4A | NM_000334.4 | c.3404G>A | p.Arg1135His | missense_variant | 18/24 | ENST00000435607.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SCN4A | ENST00000435607.3 | c.3404G>A | p.Arg1135His | missense_variant | 18/24 | 1 | NM_000334.4 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461126Hom.: 0 Cov.: 36 AF XY: 0.00000413 AC XY: 3AN XY: 726864
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 05, 2018 | The R1135H pathogenic variant in the SCN4A gene has been reported previously in the heterozygous state in individuals with hypokalaemic periodic paralysis (Matthews et al., 2009; Sung et al., 2012; Cheng et al., 2011). Functional studies done on muscle fibers from a patient harboring the R1135H pathogenic variant showed increased depolarization tendency at normal and reduced extracellular potassium compatible with the diagnosis, in addition amplitude and rise time of action potentials were reduced compared with controls (Groome et al., 2014). Expression of R1135H in mammalian cells indicate gating defects that include significantly enhanced entry into inactivation and prolonged recovery (Groome et al., 2014). The R1135H variant was not observed in approximately 6,200 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R1135H variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret R1135H as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 18, 2022 | This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In some published literature, this variant is referred to as c.3481A>G. This variant has been found in several individuals with hypokalemic periodic paralysis, including de novo cases. Assessment of experimental evidence suggests this variant results in abnormal protein function. Experiments indicate that this variant interferes with normal sodium channel function (PMID: 24549961). The variant is located in a region that is considered important for protein function and/or structure. - |
Hypokalemic periodic paralysis, type 2 Pathogenic:1Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Dec 01, 2020 | - - |
Hypokalemic periodic paralysis, type 1 Pathogenic:1
Pathogenic, no assertion criteria provided | research | Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences | Apr 12, 2022 | - - |
Familial hyperkalemic periodic paralysis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 28, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 1135 of the SCN4A protein (p.Arg1135His). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with hypokalemic periodic paralysis (PMID: 19118277, 21841462, 23516313, 24549961). In at least one individual the variant was observed to be de novo. This variant is also known as 3481A_x0005_>G. ClinVar contains an entry for this variant (Variation ID: 143201). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SCN4A protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SCN4A function (PMID: 24549961). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at